Stage (next event)
Phase 3 (Final Interim Analysis)
December 2020 (Est)
Catalyst Info & Data Links
TITLE: Remestemcel-L (mesenchymal stem cells) in COVID - Phase 3 (Final Interim Analysis)
ClinicalTrial.gov (NCT04371393): MSCs in COVID-19 ARDS
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
The proposed mechanism of action for remestemcel-L is a reduction in pathogenic inflammation mediated through the immunomodulatory activity of the MSC active ingredient. Given this mode of action, controlling the immunomodulatory bioactivity is critical to maintaining consistent product quality.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post